Cipla Limited (NSE:CIPLA)
India · Delayed Price · Currency is INR 1,221.80
-34.60 (-2.75%)
At close: Mar 23, 2026
Cipla Employees
Cipla had 30,313 employees as of March 31, 2025. The number of employees increased by 2,549 or 9.18% compared to the previous year.
Employees
30,313
Change (1Y)
2,549
Growth (1Y)
9.18%
Revenue / Employee
9.23M INR
Profits / Employee
1.50M INR
Market Cap
986.95B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 30,313 | 2,549 | 9.18% |
| Mar 31, 2024 | 27,764 | -4,559 | -14.10% |
| Mar 31, 2023 | 32,323 | 6,396 | 24.67% |
| Mar 31, 2022 | 25,927 | 255 | 0.99% |
| Mar 31, 2021 | 25,672 | -173 | -0.67% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zydus Lifesciences | 27,917 |
| Aurobindo Pharma | 27,707 |
| Mankind Pharma | 19,620 |
| Alkem Laboratories | 18,785 |
| Ipca Laboratories | 16,778 |
| Glenmark Pharmaceuticals | 15,800 |
| Divi's Laboratories | 10,542 |
| Ajanta Pharma | 9,628 |
Cipla News
- 5 days ago - Nifty 50 top losers today, March 18: Hindustan Unilever, Coal India, Cipla, NTPC and more - Business Upturn
- 6 days ago - Nifty 50 top losers today, March 17: Wipro, Cipla, Infosys, Tata Consumer Products, ITC and more - Business Upturn
- 7 days ago - FENC Settles Litigation with Cipla Over PEDMARK Generic Entry - GuruFocus
- 12 days ago - Should you buy, hold, or sell Cipla shares? Here’s what Morgan Stanley recommends - Business Upturn
- 19 days ago - Top Stocks To Buy/Sell Today: HAL, Cipla, Godrej Properties, Aster DM, Ultratech Cement, Adani Ports besides others in focus - Business Upturn
- 21 days ago - Cipla forms 60:40 JV with Kemwell Biopharma to develop and commercialise biologic products - Business Upturn
- 24 days ago - Pharma sector stocks today, Feb 27: Dr. Reddys Lab down 1.14%, Cipla falls 1.04%, Natco Pharma up 1.09% - Business Upturn
- 4 weeks ago - Cipla shares fall over 2% after USFDA classifies Greece facility inspection as OAI - Business Upturn